MARC details
| 000 -LEADER |
|---|
| fixed length control field |
01967nam a22003737a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180706s20182018 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1055-3207 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1016/j.soc.2018.02.001 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
S1055-3207(18)30011-5 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
29935680 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Peritoneal Metastases, a Frontier for Progress. [Review] |
| 251 ## - Source |
|---|
| Source |
Surgical Oncology Clinics of North America. 27(3):413-424, 2018 Jul. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Surg Oncol Clin N Am. 27(3):413-424, 2018 Jul. |
| 253 ## - Journal Name |
|---|
| Journal name |
Surgical oncology clinics of North America |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2018 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2018 |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2018-07-06 |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online through MWHC library: 2002 - present, Available in print through MWHC library: 1999 - January 2007 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Copyright (c) 2018 Elsevier Inc. All rights reserved. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
The treatments for peritoneal metastases have evolved over 30 years. Now the concepts that guided clinicians are being tested in clinical trials to optimize standardized treatment regimens. The essential features of a successful management plan are cytoreductive surgery combined with cancer chemotherapy in a large volume of intraperitoneal fluid administered into the peritoneal space. The cytotoxicity of the cancer chemotherapy is maximized by moderate hyperthermia. The patients must be carefully selected using well-defined prognostic indicators. The efforts to date are multinational with centers of excellence located throughout the world. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Neoplasms/pa [Pathology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Peritoneal Neoplasms/sc [Secondary] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Prognosis |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
Washington Cancer Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Sugarbaker, Paul H |
| 790 ## - Authors |
|---|
| All authors |
Sugarbaker PH |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1016/j.soc.2018.02.001">https://dx.doi.org/10.1016/j.soc.2018.02.001</a> |
| Public note |
https://dx.doi.org/10.1016/j.soc.2018.02.001 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
